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Background: People living with HIV are at risk of increased myo-
cardial infarction (MI). Cumulative HIV viral load (VL) has been 
proposed as a better measure of HIV inflammation than other mea-
sures of VL, like baseline VL, but its associations with MI are not 
known.
Methods: The multisite Centers for AIDS Research Network of 
Integrated Clinical Systems (CNICS) cohort includes clinical data 
and centrally adjudicated MI with distinction between atheroembolic 
MI (type 1) and MI related to supply–demand mismatch (type 2). 
We examined CNICS participants who were not on antiretroviral 
therapy (ART) at enrollment. Cumulative VL (copy-days of virus) 
from 6 months after enrollment was estimated with a time-weighted 
sum using the trapezoidal rule. We modeled associations of cumula-
tive and baseline VL with MI by type using marginal structural Cox 
models. We contrasted the 75% percentile of the VL distribution with 
the 25% percentile.
Results: Among 11,324 participants, 218 MIs occurred between 
1996 and 2016. Higher cumulative VL was associated with risk 
of all MI (hazard ratio [HR] = 1.72; 95% confidence interval 
[CI] = 1.26, 2.36), type 1 MI (HR = 1.23; 95% CI = 0.78, 1.96), and
type 2 MI (HR = 2.52; 95% CI = 1.74, 3.66). While off ART, cumula-
tive VL had a stronger association with type 1 MI (HR = 2.13; 95%
CI = 1.15, 3.94) than type 2 MI (HR = 1.25; 95% CI = 0.70, 2.25).
Baseline VL was associated with all MI (HR = 1.60; 95% CI = 1.28,
2.01), type 1 MI (HR = 1.73; 95% CI = 1.26, 2.38), and type 2 MI
(HR = 1.51; 95% CI = 1.10, 2.08).
Conclusions: Higher cumulative and baseline VL is associated with
all MI, with a particularly strong association between cumulative VL
and type 2 MI.
Keywords: Marginal structural models; myocardial infarction; HIV; 
cohort studies; inverse probability weighting
(Epidemiology 2019;30: 69–74)
Compared with the general population, people living with HIV are known to be at an increased risk of cardiovascu-
lar events including type 1 (atheroembolic) myocardial infarc-
tion (MI), as defined by the Universal Definition.1–5 While 
there is some challenge in precisely assigning MI type, a type 
1 MI is a spontaneous cardiovascular event related to athero-
sclerosis, including plaque rupture. In contrast, a type 2 MI is 
a consequence of supply-and-demand mismatch in coronary 
blood flow and may be due to causes such as sepsis or cocaine-
induced vasospasm. Both types of MI are present in people 
living with HIV, with type 2 MI being much more common in 
people living with HIV than in the general population,6,7 even 
after accounting for type 2 MIs related to substance use.
The extent to which various consequences of HIV infec-
tion contribute to the increased risk of MI is unclear. How-
ever, there is increasing evidence that inflammation is a key 
contributor to cardiovascular disease risk, both in people liv-
ing with HIV8 and in uninfected individuals.9 One source of 
inflammation in people living with HIV is elevated HIV viral 
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load. With modern HIV treatment, effective viral suppression 
may slow the progression of HIV infection to clinical AIDS 
and reduce the burden of comorbidities including cardiovas-
cular disease. Thus, it is a priority to understand the impact of 
viral load (VL) suppression from antiretroviral therapy (ART) 
on the risk of cardiovascular complications.
Other work in people living with HIV has suggested an 
adverse relation between an increased cumulative VL burden 
and key clinical outcomes. Mugavero et al.10 and Olson et al.11 
have both demonstrated an association between cumulative VL 
and mortality among people living with HIV in routine clini-
cal care. In terms of adverse cardiovascular events, Salinas et 
al.12 demonstrated that cumulative VL was associated with MI 
in a population of veterans living with HIV, although most of 
these participants were on ART at baseline and because they 
did not have a centralized adjudication process available, dis-
tinctions by MI type could not be assessed.
The goal of our study was to understand whether burden 
of cumulative VL leads to increased MI risk, particularly in 
the context of ART. We conducted this study in the Centers 
for AIDS Research Network of Integrated Clinical Systems 
(CNICS) cohort for two reasons. One, CNICS has adjudicated 
MI events—including type of MI. This is critical as previous 
work has shown that a substantial proportion, about half, of 
MI events in people living with HIV are type 2 MI events, and 
these events have different risk factors and mortality rates than 
type 1 MI events.6 Two, CNICS has a sizeable proportion of 
participants who are naive to ART at enrollment, allowing us 
to consider treated and untreated person-time separately.
METHODS
Study Population
CNICS is a prospective observational cohort that inte-
grates clinical data on >32,000 participants 18 years of age or 
older who have received routine clinical care at eight sites in the 
United States.13 The present analysis included participants who 
were ART naive at enrollment into care at one of six CNICS sites 
with comprehensive access to inpatient and outpatient electronic 
medical records and other data sources (Johns Hopkins Uni-
versity; University of Alabama at Birmingham; University of 
California, San Diego; University of California, San Francisco; 
University of North Carolina at Chapel Hill; and University of 
Washington, Seattle). Institutional review boards at each study 
site reviewed and approved CNICS protocols for patient protec-
tion and provided general approval for secondary data analysis.
Participants entered the analytic cohort after their site 
began MI surveillance (which was in 1996 at the first site) and 
after they had been enrolled in CNICS for 6 months, to allow 
time to accrue information on clinical characteristics and to 
ensure that participants were not on ART prior to cohort entry. 
The cohort entry date is referred to hereafter as “baseline.” 
Participants were censored at the earliest of any of the follow-
ing: (1) an MI; (2) death; (3) administrative date (date through 
 
which clinical data including medications, laboratory values, 
and diagnosis data were available for a site; this was a site-
specific date which varied slightly across sites but for most 
was in 2016; (4) last activity for a specific participant (the last 
date of either a laboratory value or visit date plus 9 months; 
and (5) when adjudication of MIs for their site ended (end of 
study follow-up). In addition, we censored people 8 years after 
cohort entry (based on the range of the weights in the marginal 
structure models described more below). For models estimat-
ing associations prior to ART treatment, initiation of ART was 
also a censoring criterion.
Centers for AIDS Research Network of 
Integrated Clinical Systems Data Repository
Each CNICS site captures comprehensive clinical data 
from all outpatient and inpatient encounters, including labora-
tory test results such as VL, CD4 count, cardiac biomarkers, 
medication data assessed from physician prescribing records 
and pharmacy system fill data, clinician diagnoses, and his-
torical clinical information.
Outcome
We identified the first MI event among participants in 
routine clinical care. Potential MIs were ascertained by the 
presence of either a diagnosis consistent with acute MI, a coro-
nary intervention, or an elevated cardiac biomarker. Reviewer 
packets of primary clinical data including inpatient and out-
patient provider notes, electrocardiograms, imaging and 
procedure reports, and laboratory values were created. ART 
medications were redacted from packets prior to centralized 
review to reduce potential bias. We then adjudicated potential 
events as either definite or probable MIs, classified by type of 
MI (using the five types of the Universal MI definition,5 with 
almost all events being type 1 or type 2 in this population) by 
a panel of at least two expert physician reviewers.6,7 In cases 
of discrepant findings, a third reviewer broke ties.7
Exposure
Cumulative VL (copy-days of virus in a participant) was 
estimated using measures obtained from routine care with a 
median time between VL measures of 99 days. Cumulative 
VL during follow-up was estimated with a time-weighted 
sum using the trapezoidal rule, allowing multiple measures 
in the same 6-month time period to contribute to the shape of 
the cumulative viremia distribution for that participant. This 
is the approach of both Mugavero et al.10 and Cole et al.14 
for estimating cumulative burden of viremia. We log trans-
formed, using a base 2 log, the resulting cumulative VL to 
reduce the impact of skew from extremely high outliers, as 
some (mostly ART untreated) participants had very high VL 
levels over extended periods of time. The total cumulative VL 
experienced by the participant was time-updated, using all 
VL measures available, at each 6-month time interval, across 
follow-up, to account for increased cumulative viremia over 
follow-up.
Covariates
All models included sex, race/ethnicity, clinical site, 
and age at cohort entry, diabetes, treated hypertension, statin 
use, ever-smoker, all of which were time-updated over follow-
up where appropriate. We also included lowest (nadir) CD4 
cell count at time of study entry. We defined diabetes using 
a previously validated approach as any one of the following: 
hemoglobin A1c ≥6.5%, a clinical diagnosis of diabetes and 
prescription of a diabetes-related medication, or prescription 
of a diabetes-specific medication.15 We defined treated hyper-
tension as a clinical diagnosis of hypertension and prescrip-
tion of an antihypertensive medication. Statin use was defined 
as prescription of an 3-hydroxy-3-methyl-glutaryl-coenzyme 
A (HMG-CoA) reductase inhibitor. Ever-smoker was defined 
by the presence of a tobacco use diagnosis or self-report of 
tobacco use on the CNICS clinical assessment of patient-
reported outcomes and measures,16,17 completed approxi-
mately every 6 months.18 Pack-years was collected on a large 
subset by patient-reported outcome measures. We considered 
time-updated ART as a key effect measure modifier.
Statistical Analysis
We modeled the association between cumulative VL and 
incident MI using marginal structural Cox models19 to address 
any possible time-dependent confounding of this association. 
We examined type 1 and 2 MI separately, as well as combin-
ing them in an all MI category. The pooled logistic regres-
sion approach we used to estimate these associations gives an 
approximation of the hazard ratio.20 We used 6-month time 
periods for assessing follow-up and updated cumulative VL at 
the beginning of each new time period, so follow-up time was 
always consistent between participants in each time period. 
Stabilized inverse cumulative VL weights were obtained fit-
ting linear regression models to estimate each participant’s 
density of viremia copy-days. Inverse probability weights were 
fit with logistic regression, using age, sex, site, race, smoking, 
diabetes, treated hypertension, statin use, and nadir CD4, and 
were used to adjust estimates for potential confounding. Mod-
els that included both treated and untreated participants also 
included ART in the inverse probability weight models.
Checking model assumptions, we noted that the dis-
tribution of the inverse probability weights was reasonable 
with the maximum weight observed as 96 even after fifteen 
6-month intervals of follow-up, after which we censored the 
data to avoid concerns about weak violations of the positiv-
ity assumption.21 Censoring due to large inverse probability 
weights in the more distant periods of follow-up excluded 56 
additional MI events, 34 type 1 and 22 type 2, that occurred 
after more than 8 years of follow-up. Trimming or truncation 
of weights gave comparable results,21 and few participants 
were still under follow-up after 8 years.
Cumulative VL and baseline VL have unusual distribu-
tions (online supplementary material eFigure; http://links.lww. 
com/EDE/B416, eFigure2; http://links.lww.com/EDE/B416, 
 
and eFigure3; http://links.lww.com/EDE/B416). We examined 
cumulative and baseline VL as continuous variables after log 
transform as log (VL + 1) using the base 2 log. We also cre-
ated a comparison of the 75% percentile of VL to the 25% per-
centile to give an estimate of relative effect size. This estimator 
compares the median of the top half of the distribution to the 
median of the bottom half. For the cumulative VL estimates, we 
used the distribution of cumulative VL at 5 years (which was 
the mean length of follow-up in this study).
Separately, we assessed person-time exposed to ART 
and person-time ART-untreated. We did a sensitivity analysis 
adjusting for intravenous drug use, due to population dif-
ferences between intravenous drug users and nonusers. In a 
second sensitivity analysis, we used multiple imputation to 
account for all missing data,22 which allowed us to include 
smoking pack-years as a covariate. Assumptions about the 
causal structure of the problem are presented as a supple-
ment (Supplementary Figure 4; http://links.lww.com/EDE/
B416). All analyses were performed using Stata 13 (College 
Station, TX).
RESULTS
Among 11,324 participants, 218 MIs occurred during 
a median of 4.8 years of follow-up (maximum 8 years), with 
relatively equal numbers of type 1 (n = 103) and type 2 (n = 
115) MIs. Participants mean age was 39, 79% were male, and
the majority were non-white (Table 1).
The range of cumulative VL was quite broad (Table 2). 
Median level of cumulative VL was much higher among par-
ticipants who were untreated than among the treated (10.5 mil-
lion copies/ml times days versus 1.0 million copies/ml times 
days), despite a longer period of time to accrue VL among the 
treated.
A doubling of the cumulative VL was associated with 
an increased risk of all MI (hazard ratio [HR] = 1.07; 95% 
confidence interval [CI] = 1.03, 1.11) (Table 3). The associa-
tion of VL with type 1 MI was attenuated (HR = 1.02; 95% 
CI = 0.97, 1.08), but higher cumulative VL was associated 
with type 2 MI (HR = 1.11; 95% CI = 1.07, 1.16). The HR for 
all MI contrasting participants in the 75th percentile versus 
the 25th percentile of cumulative VL (calibrated to 5 years of 
follow-up) was 1.72 (95% CI = 1.26, 2.36). The association 
with cumulative viral load was weaker for type 1 MI (HR = 
1.23; 95% CI = 0.78, 1.96) than for type 2 MI (HR = 2.52; 
95% CI = 1.74, 3.66).
As VL accumulates differently among participants 
on versus off ART, we also looked at time periods in which 
participants were treated with ART and untreated with ART. 
Among the 3168 participants who were off ART for at least 
one 6-month follow-up interval, during the person-time at risk 
in their unexposed period, doubling of the cumulative VL was 
associated with all MI (HR = 1.09; 95% CI = 0.99, 1.21), type 
1 MI (HR = 1.18; 95% CI = 1.03, 1.35), and with type 2 MI 
(HR = 1.05; 95% CI = 0.93, 1.20), although some intervals 
were consistent with null associations (Table 3). While off 
ART, contrasting participants in the 75th percentile versus 
the 25th percentile of cumulative VL, there was a stronger 
association with type 1 MI (HR = 2.13; 95% CI = 1.15, 3.94) 
than type 2 MI (HR = 1.25; 95% CI = 0.70, 2.25). Among 
the 9931 participants with at least 6 months of ART exposure 
during follow-up, we considered the person-time at risk in 
the exposed period. VL accounting began at the start of ART 
treatment (using an intention to treat definition of exposure) in 
this analysis, so median VL at end of follow-up was lower than 
in the full cohort analysis (Table 2). In these participants, dou-
bling of the cumulative VL was associated with all MI (HR = 
1.06; 95% CI = 1.02, 1.10), type 1 MI (HR = 1.02; 95% CI = 
0.97, 1.08), and type 2 MI (HR = 1.10; 95% CI = 1.06, 1.15).
We also considered baseline VL as an alternative measure 
because it is commonly used in the HIV literature. Baseline VL 
was associated with an increase in all MI events using a Cox 
proportional hazards model of HR = 1.06 (95%  CI = 1.03, 1.09) 
per doubling of VL (Table 4). If we look at the 75% percen-
tile of baseline VL (when compared with the 25% percentile of 
baseline VL) then the HR for all MI was 1.60 (95% CI = 1.28, 
2.01), and this was driven by both type 1 MI (HR = 1.73; 95% 
CI = 1.26, 2.38) and type 2 MI (HR = 1.51; 95% CI = 1.10, 2.08).
Results for the primary analysis were similar with 
imputation for missing data (eTable 1; http://links.lww.com/
EDE/B416). The sensitivity analysis that also adjusted for 
intravenous drug use did not demonstrate any appreciable dif-
ference in estimates. We also considered mortality rates over 
follow-up, so competing risk concerns could be considered 
if there were large differences in mortality in the treated ver-
sus untreated participants. There were 15.3 deaths per 1000 
person-years (95% CI = 14.4, 16.3) and were similar for 
participants who were off ART (14.4 death per 1000 person-
years; 95% CI = 12.1, 17.1) and on ART (15.4 deaths per 1000 
person-years; 95% CI = 14.4, 16.5).
DISCUSSION
The goal of our study was to understand whether the bur-
den of cumulative VL in the context of ART leads to increased 
MI risk. Among people living with HIV in the CNICS cohort 
who were not on ART at enrollment, greater cumulative VL 
was associated with increased risk of all MI events. Effect 
sizes varied depending on ART treatment during follow-up 
and type of MI, with type 2 MI generally showing larger asso-
ciations than type 1 MI. However, all participants appeared 
to benefit from lower cumulative VL in terms of reduced MI 
risk. The differences in MI events may be one element of the 
increased all-cause mortality among participants with high 
cumulative VL,23 which appears to be associated with cardio-
vascular events regardless of treatment status.
These findings may help explain in small part how the 
burden of HIV infection has evolved over time with earlier ini-
tiation of effective treatments for HIV in clinical care for people 
living with HIV in the United States. The presence of untreated 
person-time allowed us to examine the burden of HIV infection 
prior to effective HIV treatment. Our results suggest that, in par-
ticipants who are not treated, greater VL is associated with an 
increased risk of type 1 MI. Active treatment seems to attenuate 
the association of cumulative viremia with type 1 MI, in gen-
eral, although the participants are also exposed to much lower 
VL levels under treatment. Baseline measures of VL showed an 
TABLE 2. Cumulative viral load (VL, Million Copies/ml Times Days) at the End of Follow-Up for All Participants, the End of the  












Time for Time  
Period
All person-time 40.8 2.0 140 0.002 to 6380 4.8 years
ART exposed person-time 36.1 1.0 140 0.002 to 6380 4.4 years
ART unexposed person-time 37.1 10.5 84.8 0.002 to 1550 1.8 years
ART indicates antiretroviral therapy.
TABLE 1. Baseline Demographic and Clinical Characteristics 
of People Living with HIV Who Were Not on ART at Entry 
from the CNICS Cohort Across the United States
Characteristic Overall
N 11,324
Age, years, mean (SD) 39 (10)
Nadir CD4 count (cells/mm3) Mean (SD) 315 (245)







Former smoker, % 24
Current smoker, % 38
Diabetes, % 4
Treated hypertension, % 10
Treated dyslipidemia, % 4
ART indicates antiretroviral therapy, SD standard deviation, VL viral load.
association with MI, but it was slightly weaker for all MI and for 
type 2 MI than with the cumulative viral load measures.
Our findings are in accordance with previous evidence 
that chronic viremia is related to atherosclerotic disease. 
Human cohort studies show atherosclerotic links to inflamma-
tion both in people living with HIV24 and those not infected 
with HIV,25 which could well be a plausible pathway by which 
cumulative VL could increase cardiovascular risk.
Our study has several strengths, including adjudication 
of MIs and classification of MI type, a large population of 
ART-naive participants, and extensive follow-up. Informa-
tion on ART exposure was derived from clinical records and 
thus represents the actual treatment intentions of the provider. 
Extensive measurement of participant characteristics, includ-
ing laboratory measures and patient-reported outcomes, 
allowed for rich confounding control and an understanding of 
possible imbalances among cardiovascular risk factors among 
those with and without high burdens of viremia.
The limitations of this study include the observational 
nature of the data, the lack of pre-enrollment VL measures, the 
predominantly male composition of CNICS, and the irregular 
pattern of VL measurements. We did not include sudden cardiac 
death in our MI outcome because it can be difficult to distinguish 
cardiac causes of death from other causes such as drug overdoses. 
The use of an ever-smoking definition was also suboptimal, 
although results were similar when multiple imputation was used 
to account for missing smoking data among some participants.
We cannot rule out that some ART regimens may be less 
cardioprotective than others, relative to untreated people liv-
ing with HIV, for atheroembolic MI.26,27 Thus, choice of ART 
regarding cardiovascular risk is still important, although remain-
ing untreated would not be supported by these data as there were 
4.9 MI events per 1000 person-years off ART and 3.9 MI events 
per 1000 person-years on ART, demonstrating that treatment is 
TABLE 3. Association Between Cumulative VL and MI in 11,324 People Living with HIV Who Were Not on ART at Cohort Entry, 




HR for 75th 
vs 25th %ile 95% CI
MI Rate per 1000 
Person-Years  
(95% CI)
All participants ART untreated at baseline (52,952 person-years of follow-up, 218 MIs, 103 type 1, 115 type 2)
 All MI 1.07 1.03, 1.11 1.72 1.26, 2.36 4.12 (3.61, 4.70)
 Type 1 MI 1.02 0.97, 1.08 1.23 0.78, 1.96 1.94 (1.60, 2.36)





(75 vs 25) 95% CI
Rate per 1000 
Person-Years
Person-time off ART (8270 person-years of follow-up, 41 MIs, 15 type 1, 26 type 2)
 All MI 1.09 0.99, 1.21 1.48 0.93, 2.35 4.96 (3.65, 6.73)
 Type 1 MI 1.18 1.03, 1.35 2.13 1.15, 3.94 1.81 (1.09, 3.01)




HR for 75th 
vs 25th %ile 95% CI
MI Rate per 1000 
Person-Years  
(95% CI)
Person-time on ART (44,674 person-years of follow-up, 177 MIs, 88 type 1, 89 type 2)
 All MI 1.06 1.02, 1.10 1.65 1.22, 2.23 3.96 (3.42, 4.59)
 Type 1 MI 1.02 0.97, 1.08 1.22 0.78, 1.91 1.97 (1.60, 2.43)
 Type 2 MI 1.10 1.06, 1.15 2.31 1.59, 3.35 1.99 (1.62, 2.45)
Adjusted HRs
a and 95% CIs are provided both for doubling the cumulative VL and for the 75th versus the 25th percentile of the cumulative VL distribution.
aEstimates are adjusted for age, sex, race/ethnicity, clinical site, diabetes, treated hypertension, statin use, ever-smoker, and lowest CD4 cell count. The all MI model is also adjusted 
for ART.
ART indicates antiretroviral therapy, CI confidence interval, HR hazard ratio, MI myocardial infarction, VL viral load.
TABLE 4. Association Between Baseline Viral Load and MI 
in 11,324 People Living with HIV Who Were Not on ART at 
Cohort Entry
Outcome
HR per  
Doubling 95% CI
HR for 75th 
vs 25th %ile 95% CI
MI Rate per 1000 
Person-Years  
(95% CI)
All participants ART-untreated at baseline (63,528 person-years of follow-
up, 274 MIs, 137 type 1, 137 type 2)
 All MI 1.06 1.03, 1.09 1.60 1.28, 2.01 4.3 (3.8, 4.9)
 Type 1 MI 1.07 1.03, 1.11 1.73 1.26, 2.38 2.2 (1.8, 2.5)
 Type 2 MI 1.05 1.01, 1.09 1.51 1.10, 2.08 2.2 (1.8, 2.5)
Adjusted HRs (estimates are adjusted for age, sex, race/ethnicity, clinical site, 
diabetes, treated hypertension, statin use, ever-smoker, and lowest CD4 cell count. The 
all MI model is also adjusted for ART) and 95% CIs are provided both for doubling the 
cumulative VL and for the 75th versus the 25th percentile of the baseline VL distribution.
ART indicates antiretroviral therapy, CI confidence interval, HR hazard ratio, MI 
myocardial infarction, VL viral load.
associated with protection from cardiovascular events in gen-
eral. Perhaps improvements in the cardiovascular risk profile of 
newer ART approaches may further improve outcomes. It is also 
possible that single episodes of extremely high viremia may be 
important, but this is difficult to assess in irregular data.
Higher VL is associated with a higher risk of MI among 
people living with HIV. Higher cumulative VL is more strongly 
associated with type 2 MI, as opposed to type 1, highlighting 
the importance of examining MIs by type.
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